



December 28, 2021

**BSE Limited**

Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400 001  
Scrip code: 532531

**The National Stock Exchange of India Limited**

Exchange Plaza, Bandra-Kurla Complex  
Bandra (E) Mumbai - 400 051  
Scrip code: STAR

Dear Madam/ Sir,

**Sub: Press Release**

Please find attached Press Release issued by the Company titled:

**“Strides receives DCGI approval under EUA to commercialize  
Molnupiravir, an oral medication for Covid-19”**

Thanks & Regards,

For **Strides Pharma Science Limited,**

A handwritten signature in blue ink that reads 'Manjula R.'.

**Manjula Ramamurthy**  
**Company Secretary**



Encl. As above

**Strides Pharma Science Limited**

CIN: L24230MH1990PLC057062

Corp Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru - 560 076, India | Tel: +91 80 6784 0000 Fax: +91 80 6784 0700  
Regd Off: 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, India | Tel: +91 22 2789 2924 / 3199 Fax: +91 22 2789 2942

corpcomm@strides.com, www.strides.com

## Strides receives DCGI approval under EUA to commercialize Molnupiravir, an oral medication for Covid-19

- Molnupiravir is an approved oral drug in UK & was recently granted Emergency Use Authorization (EUA) by USFDA for the treatment of High-Risk Adults with Mild to Moderate COVID-19
- Strides to immediately launch Molnupiravir in India under its brand Stripiravir™

**BENGALURU, INDIA– December 28, 2021** – Strides Pharma Science Limited (BSE: 532531, NSE: STAR, Company or Strides), a global pharmaceutical company, today announced that it has received Emergency Use Authorization from the Drugs Controller General of India (DCGI) to launch Molnupiravir 200mg in India. Molnupiravir is an orally administered form of a potent ribonucleoside analog that inhibits the replication of SARS-CoV-2 and the clinical studies have shown this drug to be active against the most common Covid-19 variants.

Under the brand name **Stripiravir™**, Strides has developed Molnupiravir and is commercializing the product with a group integrated supply chain for Active Pharmaceutical Ingredients and solid oral dosage from its large-scale WHO Pre-Qualified (PQ) manufacturing capacities.

**Dr. R Ananthanarayanan, Managing Director & Chief Executive Officer, Strides Pharma Science Limited** said “We are delighted to receive the DCGI approval for launching Molnupiravir, which has shown promising results in several clinical studies. The product provides therapeutic benefit to the patients with mild to moderate Covid symptoms and can be administered at home. With the emergence of the new variants, we believe Molnupiravir will benefit the broad population which could be at risk due to Covid-19. We remain committed in our fight against this global pandemic.”

Molnupiravir has been granted approval by the UK's Medicines and Healthcare products Regulatory Agency (MHRA) as a safe and effective medication for patients with mild to moderate cases of COVID-19. The product also recently received the USFDA's Emergency Use Authorization. The drug was invented by Emory University (Atlanta, USA) and was developed by Merck & Co., Inc.<sup>1</sup> in collaboration with Ridgeback Biotherapeutics.

### About Strides

Strides, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bengaluru, India. The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy along with an institutional business to service donor-funded markets. The Company's global manufacturing sites are located in India (Chennai, Puducherry and two locations in Bengaluru), Singapore, Italy (Milan), Kenya (Nairobi) and the United States (New York). The Company focusses on “difficult to manufacture” products that are sold in over 100 countries. Additional information is available at the Company's website at [www.strides.com](http://www.strides.com)

### For further information, please contact:

<p><b>Investor Relations</b> <b>Badree Komandur</b>, Executive Director &amp; Group CFO, Strides +91 80 6784 0747 <b>Sandeep Baid</b>, Investor Relations, Strides +91 80 6784 0791, <a href="mailto:sandeep.baid@strides.com">sandeep.baid@strides.com</a></p> <p><b>Strides Pharma Science Limited</b> CIN: L24230MH1990PLC057062 Regd. Office: 201, 'Devavrata', Sector - 17, Vashi, Navi Mumbai - 400 703 Corp. Office: Strides House, Bannerghatta Road, Bengaluru – 560076</p>	<p><b>Corporate Communication</b> <b>Pallavi Panchmatia</b>, Corporate Communication, Strides +91 80 6784 0193, <a href="mailto:pallavi.panchmatia@strides.com">pallavi.panchmatia@strides.com</a></p> <p><b>PR Consultancy</b> Fortuna PR K Srinivas Reddy: +91 90005 27213 <a href="mailto:srinivas@fortunapr.com">srinivas@fortunapr.com</a> K Priya: +91 95354 25418 <a href="mailto:priya@fortunapr.com">priya@fortunapr.com</a></p>
--	---

<sup>1</sup> Merck is known as MSD outside the United States and Canada